PDC*line Pharma Unveils New Clinical Results with PDC*lung01 at the European Lung Cancer Congress 2025
March 23rd 2025, PDC*line Pharma is presenting new results from its ongoing clinical development program at the European Lung Cancer Congress 2025, during the poster session — in the presence of our Principal Investigator, Prof. Johan Vansteenkiste. PDC*line Pharma is sharing key findings on PDC*lung01, its innovative, "off-the-shelf" therapeutic cancer vaccine for non-small cell lung cancer (NSCLC).
Poster Title: Primary analysis of safety, efficacy and immunogenicity of the therapeutic cancer vaccine PDClung01 with or without pembrolizumab in NSCLC: A multicenter phase I/II study
Key highlights from the study:
- In Cohort B2, the confirmed Overall Response Rate (ORR) of 55% and the median Progression-Free Survival (mPFS) of 8.87 months represent an improvement of 16% in ORR and 2.4 months in mPFS compared to the Keynote-042 PD-L1 ≥50% population.
- PDC*lung01 combined with pembrolizumab provides meaningful clinical activity in untreated PD-L1 ≥50% stage IV NSCLC, with a mild safety profile, and a confirmed correlation between the immune response intensity and the PFS.
The poster presented is available here: Poster_ELCC2025.pdf
PDC*line Pharma is look forward to engaging with fellow researchers, clinicians, and industry leaders at ELCC 2025 to discuss how PDC*lung01 may help shape the future of immuno-oncology.
About the European Lung Cancer Congress 2025
The European Lung Cancer Congress 2025 is taking place in Paris, France from 26-29 March 2029.
The European Lung Cancer Congress is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.
Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians / pneumologists, interventional radiologists and pathologists all benefit from its comprehensive and stimulating programme.
